新诊断晚期卵巢癌患者新辅助化疗后行HIPEC与可接受的毒性和良好的生活质量相关
这项II期试验纳入20例无法首选直接肿瘤细胞减灭术的IIIC或IVA期上皮性卵巢癌患者,接受3-6周期含铂双药新辅助化疗后行肿瘤细胞减灭术联合卡铂HIPEC(800 mg/m2,90分钟)。12例(70.6%)发生3或4级毒性,以贫血(59%)、血小板减少(29%)和低钾血症(24%)最常见;围手术期无死亡,FACT-O等生活质量评分无显著变化,中位无进展生存期为11.2个月。
要点
- 3-6周期新辅助化疗后行肿瘤细胞减灭术联合卡铂HIPEC,20例均成功完成,围手术期无死亡。
- 12例(70.6%)发生3或4级毒性,最常见为贫血(59%)、血小板减少(29%)、低钾血症(24%)。
- 术后6周、3个月、6个月FACT-O、NTX、AD评分较术前无显著变化,中位无进展生存期11.2个月。
核心结论
- 在间隔性肿瘤细胞减灭术中加用卡铂HIPEC在该患者人群中耐受良好,骨髓抑制是最常见的不良事件,且未对生活质量指标产生不良影响;作者认为该方案疗效需在更大规模临床试验中进一步评估。
研究设计与样本
- II期试验,纳入20例不适合首选肿瘤细胞减灭术的IIIC或IVA期上皮性卵巢癌患者,接受3-6周期含铂双药新辅助化疗后行肿瘤细胞减灭术联合卡铂HIPEC(800 mg/m2,90分钟),随访至少12个月。
主要发现
- 20例患者均成功完成HIPEC,围手术期无死亡。
- 12例(70.6%)发生3或4级毒性,最常见为贫血(59%)、血小板减少(29%)和低钾血症(24%)。
- 术前与术后6周、3个月、6个月的FACT-O、NTX、AD评分无显著变化。
- 截至报告时9例(45%)出现疾病复发,中位无进展生存期为11.2个月(范围2.5-23.7个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出该方案疗效需在更大规模临床试验中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate toxicity, quality of life and PFS in patients with advanced ovarian cancer who underwent neoadjuvant chemotherapy (NAC) followed by CRS and HIPEC with carboplatin. METHODS: Patients with stage IIIC or IVA epithelial ovarian cancer, who were not candidates for primary CRS, were enrolled in this phase two trial. Patients received 3-6 cycles of NAC with an IV carboplatin doublet followed by CRS with HIPEC (carboplatin 800 mg/m2 for 90 min). They were followed for at least 12 months to assess for adverse events, quality of life (QOL) and disease progression. QOL was measured using the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaires prior to CRS and post-operatively at 6 weeks, 3 months, and 6 months after CRS. RESULTS: Twenty patients were enrolled. HIPEC was completed successfully in all twenty patients, and there was no peri-operative mortality. Twelve (70.6%) patients experienced a grade 3 or 4 toxicity; most commonly anemia (59%), thrombocytopenia (29%), and hypokalemia (24%). There was no significant change between the pre-operative and postoperative 6 weeks, 3 month, and 6 month FACT-O, NTX, and AD scores. Nine (45%) patients have experienced disease recurrence to date. The median progression free survival in this cohort is 11.2 months (2.5-23.7 months). CONCLUSION: The addition of HIPEC with carboplatin to interval CRS was well tolerated in patient population. Myelosuppression was the most common adverse event. CRS with HIPEC did not adversely impact these patients' QOL indices. The efficacy of this regimen should be further evaluated in a larger clinical trial.
引用
- Menzies AV, Usher EC, Hsu FC, et al. HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients. Gynecol Oncol. 2022. PMID: 36085091. doi:10.1016/j.ygyno.2022.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。